Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Patent
1994-09-28
1997-05-27
Sayala, Chhaya D.
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
424 857, 424427, A61K 3821
Patent
active
056329849
ABSTRACT:
Intraocular administration of drugs such as .alpha.-2a interferon is employed in the treatment of age-related macular degeneration. Intraocular administration obviates the side effects associated with systemic administration, concentrates the drug at the site of the disease, and, where microcapsules are employed, provides continuous, long-lasting treatment.
REFERENCES:
patent: 4853224 (1989-08-01), Wong
Baron et al., "The Interferons: Mechanism of Action and Clinical Applications", J. of the Am. Medical Assoc., 266:1375 (1991).
Brouty-Boy e and Zetter, "Inhibition of Cell Motility by Interferon", Science, 208:516-518 (1980).
Celtrix News Release, "Celtrix Acquires Baltimore Biotech and Announces Human Studies to Treat Macular Degeneration", Sep. 14, 1992.
Dayton, "Treatment for Blindness Challenges Eye Orthodoxy", New Scientist, Mar. 21 Issue, p. 21 (1992).
Engler et al., "Interferon Alpha-2a Treatment of Patients with Subfoveal Neovascular Macular Degeneration", Acta Ophthalmologica, 71:27-31 (1993).
Folkman and Klagsbrun, "Angiogenic Factors", Science, 235:442-447 (1987).
Fung, "Interferon Alpha 2a for Treatment of Age-Related Macular Degeneration", Am. J. of Ophthalmology, 112(3):349-350 (1991).
Glazer et al., "Transforming Growth Factor-.beta..sub.2 for the Treatment of Full-thickness Macular Holes", Ophthalmology, 99(7):1162-1173 (1992).
Guyer et al., "Interferon-Associated Retinopathy", Arch Ophthalmology, 111:350-356 (1993).
Guyer et al., "Systemic Antiangiogenic Therapy for Choroidal Neovascularization", Arch Ophthalmology, 110:1383-1384 (1992).
Heller, "Biodegradable Polymers in Controlled Drug Delivery", CRC Critical Reviews in Therapeutic Drug Carrier Systems, vol. 1, CRC Press, Boca Raton, FL, pp. 39-90 (1987).
Heller, "Bioerodible Hydrogels", Hydrogels in Medicine and Pharmacy, vol. III, N.A. Peppes ed., CRC Press, Boca Raton, FL, pp. 137-149 (1987).
Kara.cedilla.orlu, MD, "Lack of Toxicity of Intravitreally Administered Interferon Alpha-2a", Ophthalmic Surgery, 23(12):833-835 (1992).
Loughnan et al., "Treatment of Subfoveal Choroidal Neovascular Membranes with Systemic Interferon-.alpha.2a", Aust. and New Zea. J. of Ophthalmol., 20(3):173-175 (1992).
Penn et al., "The Mystery of Pre-Retinal Neovascularization in the Rat Model of Retinopathy of Prematurity", Association for Research in Vision and Ophthalmology, Annual Meeting Abstracts , Paper #2937 published in Invest. Ophthalmol. & Visual Science, vol. 33 (1992).
Reynaud et al., "Intermittent Hypoxia Stimulates Neovascularization in the Rat Model of Retinopathy of Prematurity", Association for Research in Vision and Ophthalmology, Annual Meeting Abstracts, Paper #2940 published in Invest. Ophthalmol. & Visual Science, vol. 33 (1992).
Sabbagh, "Know When Interferon Treatment Can Succeed for ARMD: Prognosis is Best for Immature and Most Choroidal Neovascular Membranes", Ophthalmology Times, Mar. 1 Issue, p. 6 (1993).
Thomas and Ibanez, "Interferon Alfa-2a in the Treatment of Subfoveal Choroidal Neovascularization", Am. J. of Ophthalmol., 115:563-568 (1993).
White et al., "Treatment of Childhood Angiomatous Diseases with Recombinant Interferon Alfa-2a", The J. of Pediatrics, 118(1):59-66 (1991).
White et al., "Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alpha-2a", N.E. Journal of Medicine, 320:1197 (1989).
Williams et al., "Effect of Plasminogen Activator Inhibitor Type 2 (PAI-2) on Neovascularization", Association for Research in Vision and Ophthalmology, Annual Meeting Abstracts, Paper #1942 published in Invest. Ophthalmol. & Visual Science, vol. 33 (1992).
Bioworld, "Growth Factor slows Retinal Degeneration", vol. 2, #195, 1990.
Poliner et al Ophthalmology (1993) vol. 100, 1417-1424.
Gillies et al Br. J. Ophthalmol (1993) 77, pp. 759-765.
Guyer et al Arch Ophthalmol (1992) 110, pp. 1383-1384.
Smith et al., Cornea, 8(1), pp. 58-61, 1989.
Vegh et al., Ophthalmic Surg., 17(2) pp. 103-105, 1986.
Dharma et al., Ophthalmic Surg., 18(1), pp. 51-54, 1987.
Gin Jerry B.
Lee King Y.
Wong Vernon G.
Oculex Pharmaceuticals, Inc.
Rowland Bertram I.
Sayala Chhaya D.
LandOfFree
Method of treatment of macular degeneration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of macular degeneration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of macular degeneration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2327170